Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 3/20 | 0.48 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | G6PD | P11413 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TPMT | P51580 | 1/20 | 0.40 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.39 |
| ▸ | PLIN1 | O60240 | 1/20 | 0.39 |
| ▸ | CACNA1F | O60840 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31451704 | 0.84 | MAPT (0.49) | MAPTL3MBTL1SMN1; SMN2POLBKMT2A | |
| SCHEMBL3520372 | 0.84 | SMN1; SMN2 (0.48) | MAPTL3MBTL1SMN1; SMN2POLBKMT2A | |
| SCHEMBL17375014 | 0.84 | MAPT (0.49) | MAPTL3MBTL1SMN1; SMN2POLBKMT2A | |
| SCHEMBL2624003 | 0.84 | L3MBTL1 (0.42) | MAPTL3MBTL1SMN1; SMN2POLBCTSB | |
| SCHEMBL1868433 | 0.84 | ALDH1A1 (0.41) | MAPTL3MBTL1SMN1; SMN2POLBCTSB | |
| SCHEMBL3985537 | 0.82 | KDM4E (0.46) | MAPTL3MBTL1SMN1; SMN2POLBKDM4E | |
| SCHEMBL3516661 | 0.81 | SMN1; SMN2 (0.44) | MAPTL3MBTL1SMN1; SMN2POLBKMT2A | |
| SCHEMBL11144125 | 0.81 | ALDH1A1 (0.45) | MAPTL3MBTL1SMN1; SMN2POLBCTSB | |
| SCHEMBL3518479 | 0.80 | KDM4E (0.45) | MAPTL3MBTL1SMN1; SMN2POLBKDM4E | |
| SCHEMBL7823436 | 0.78 | MAPT (0.56) | MAPTL3MBTL1SMN1; SMN2POLBKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101983384-A | Prolyl hydroxylase inhibitors | SMITHKLINE BEECHAM CORP | 2011-03-02 | — | — | CN | disclosed |
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | Glaxo Smith Kline LLC., a corporation | 2011-02-17 | — | — | US | disclosed |
| EP-2273879-A1 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2011-01-19 | — | — | EP | disclosed |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | SMITHKLINE BEECHAM CORPORATION | 2010-12-02 | — | — | US | disclosed |
| EP-2227770-A2 | PROLYL HYDROXYLASE INHIBITORS | GlaxoSmithKline LLC (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009134850-A1 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-11-05 | — | — | WO | disclosed |
| WO-2009073497-A2 | PROLYL HYDROXYLASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039895-A1 | PROLYL HYDROXYLASE INHIBITORS | HIF1AN, EGLN3, EGLN2 | MAPT 4507/4885L3MBTL1 2303/4885SMN1; SMN2 3216/4885 |
| US-20100305133-A1 | Prolyl Hydroxylase Inhibitors | HIF1AN, EGLN3, EGLN2 | MAPT 4697/4885L3MBTL1 2715/4885SMN1; SMN2 3777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.